Non Interventional Post Marketing Programme in Acromegaly
NCT00747500 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42
Last updated 2019-01-07
Summary
The purpose of this study, is to assess the safety and local tolerability of the long-term use of Somatuline Autogel when administered by patients or their partners ("Home Injection Group") and the safety and local tolerability in patients receiving their injection from a healthcare professional (HCP) ("Reference Group").
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ipsen Medical Director · Ipsen
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-07-31
- Primary Completion
- 2012-09-30
- Completion
- 2013-03-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Study in Polish Acromegalic Patients Treated With Somatuline Autogel
NCT01333384 ·Status: COMPLETED
-
Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
NCT02807233 ·Status: COMPLETED
-
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
NCT00210457 ·Status: COMPLETED ·Phase: PHASE3
-
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
NCT00383708 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
NCT00234572 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
NCT00216398 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
NCT00701363 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
NCT02493517 ·Status: COMPLETED ·Phase: PHASE3
-
Predictive Factors Study
NCT02020499 ·Status: TERMINATED
-
Non Interventional Study For Patients Treated With Somavert®
NCT00858143 ·Status: COMPLETED
-
Treatment Patterns and Treatment Outcomes for Acromegaly
NCT03043586 ·Status: COMPLETED
-
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
NCT01995734 ·Status: APPROVED_FOR_MARKETING
-
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
NCT00499993 ·Status: COMPLETED ·Phase: PHASE3
-
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
NCT00690898 ·Status: COMPLETED ·Phase: PHASE3
-
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
NCT00151437 ·Status: COMPLETED ·Phase: PHASE4
-
One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
NCT01471405 ·Status: COMPLETED
-
Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
NCT00627796 ·Status: COMPLETED ·Phase: PHASE4
-
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
NCT00500227 ·Status: COMPLETED
-
A Prospective Study of Outcome After Therapy for Acromegaly
NCT01809808 ·Status: COMPLETED
-
A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency
NCT00455884 ·Status: COMPLETED
-
Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects
NCT01723748 ·Status: COMPLETED ·Phase: NA
-
A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
NCT01861717 ·Status: TERMINATED ·Phase: PHASE4
-
Acute Application of Pegvisomant and Octreotide in Acromegaly
NCT00595140 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly
NCT04003519 ·Status: WITHDRAWN
-
A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders
NCT00455728 ·Status: COMPLETED